https://orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj <p>Orapuh Journal (Orap J) is an open-access, internationally peer-reviewed online journal dedicated to oral and public health. The journal provides accessible, high-quality, peer-reviewed knowledge to oral and public health professionals, educators, consumers, and the global community.</p> <p><strong>Aim</strong><br>Orapuh Journal aims to enhance access to superior information and research in oral and public health while fostering the development of emerging researchers and authors, particularly from underserved areas within these disciplines.</p> <p><strong>Scope</strong><br>Orapuh Journal prioritises:</p> <p>1. Original research<br>2. Comprehensive and critical review articles<br>3. Evidence-based information<br>4. Interactive clinical and related content<br>5. Content contributions focused on advancing oral and public health disciplines.</p> <p><strong>Open Access Information</strong></p> <p>All articles in Orap J are open-access articles distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License.</p> <p>Click <a href="https://www.orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj/about"><strong>here</strong></a> to read more about the Journal. Find out <a href="http://orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj/why-choose">why <em>Orap J</em> is your quick access to being</a>!</p> <p><strong><a href="https://orapuh.org/2023/11/01/the-vital-role-of-communicating-dental-and-public-health-research-findings/">Click here</a></strong>&nbsp;to read an article about the vital role of communicating oral and public health research findings to the scientific community.</p> <p><a href="http://orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj/editorial-policies">Editorial Policies</a>&nbsp; | <a href="https://orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj/about/editorialTeam">Editorial Team</a> | <a href="http://orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj/about/submissions">Author Guidelines</a></p> en-US <p>Authors of articles published in <em>Orap J</em> are the copyright holders of their articles. When they accept our terms of use, they grant any third party the right to use, reproduce or disseminate their article freely without fiscal or registration restrictions.</p> <p>&nbsp;</p> [email protected] (Prof. V. E. Adamu) [email protected] (Editor-in-Chief) Thu, 28 Aug 2025 17:07:52 +0200 OJS 3.1.2.4 http://blogs.law.harvard.edu/tech/rss 60 https://orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj/article/view/e1281 <p><strong>Introduction </strong></p> <p>Preeclampsia (PE) is a serious pregnancy complication associated with significant risks for both mothers and fetuses. Identifying biological markers that predict adverse outcomes is essential for improving clinical management and outcomes in severe preeclampsia.</p> <p><strong>Purpose </strong></p> <p>This study aimed to identify blood and urine biological markers that are strongly associated with maternal-fetal complications among women with severe preeclampsia.</p> <p><strong>Methods </strong></p> <p>A total of 204 pregnant women hospitalized for severe preeclampsia were included. Demographic, clinical, and laboratory data were collected. Univariate and multivariate logistic regression analyses were performed to determine biological predictors of maternal-fetal complications.</p> <p><strong>Results </strong></p> <p>The mean age of participants was 28 ± 6.7 years, with 53.8% being primiparous. A history of preeclampsia was present in 19.2% of patients, and 63.5% had chronic hypertension. The median gestational age at diagnosis was 32 weeks (range: 28–36 weeks). Overall, 53.8% of patients experienced complications, most commonly retroplacental hematoma (14.4%), eclampsia (11.5%), and acute renal failure (10.6%). Biological markers significantly associated with maternal-fetal complications were uric acid &gt; 6 mg/dl (p = 0.006), AST &gt; 40 IU/L (p = 0.017), creatinine ≥ 1.3 mg/dl (p = 0.037), proteinuria ≥ 3 g/24h (p = 0.023), and ACR ≥ 30 (p = 0.023). After multivariate adjustment, three markers remained independently associated with complications: uric acid &gt; 6 mg/dl (ORa: 2.26; 95% CI: 1.05–4.87), AST &gt; 40 IU/L (ORa: 2.43; 95% CI: 1.02–5.76), and ACR ≥ 30 (ORa: 2.95; 95% CI: 1.21–7.19).</p> <p><strong>Conclusion </strong></p> <p>Preeclampsia remains a complex condition requiring vigilant monitoring. Elevated uric acid, AST, and ACR were identified as independent predictors of maternal-fetal complications and may serve as valuable markers for risk stratification. These findings support the integration of biomarker assessment into management strategies, while future research should evaluate additional markers and personalized protocols to improve maternal and perinatal outcomes.</p> Dophie Beya Tshibuela, Jérémie Masidi Muwonga, Passy Kimema, Aliocha Natuhoyila Nkodila, Fons Verdonck, Bernard Spitz, Jean Pierre Moyene Elongi Copyright (c) 2025 Dophie Beya Tshibuela, Jérémie Masidi Muwonga, Passy Kimema, Aliocha Natuhoyila Nkodila, Fons Verdonck, Bernard Spitz, Jean Pierre Moyene Elongi https://creativecommons.org/licenses/by-nc/4.0 https://orapuh.org/ojs/ojs-3.1.2-4/index.php/orapj/article/view/e1281 Thu, 28 Aug 2025 17:06:46 +0200